Uncategorized
Ocular Therapeutix pursues opportunities to spur innovation, development
After completing an initial public offering in July 2014, Ocular Therapeutix is prepared to forge ahead with research and development and execute plans to market novel drug delivery products from the platform that is the company’s hallmark.Although some losses related to research and development are expected, the company plans to devote newly available capital to drive innovation and carve new therapeutic niches in ophthalmology.